Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression.

CONCLUSIONS: The expression of PSA, PSMA, EGFR and AR on CTCs appears to be absent in the pretreatment samplings in cases of localized prostate cancer. The same markers are hyper-expressed before treatment mostly in metastatic prostate cancer and can relate with early biochemical relapse. PMID: 31144490 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31144490?dopt=Abstract

Source: Minerva Urologica e Nefrologica - June 1, 2019 Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research